Trial Information
Randomized Multi-Center Study Comparing Prolonged Primary Systemic Endocrine Therapy With Letrozole Alone or in Combination With Zoledronic Acid in Early Breast Cancer (NEOadjuvant Study in CANada)
Inclusion Criteria
Inclusion Criteria
- Postmenopausal women
- Newly diagnosed with non metastatic breast cancer
- Candidate for mastectomy or breast-conserving surgery
Exclusion Criteria
- Patients with invasive tumors
- Patients receiving anti-cancer treatment
- Patients who have undergone surgery
Other protocol-defined exclusion criteria may apply.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Clinical response at 24 weeks
Principal Investigator
Novartis
Investigator Role:
Study Chair
Investigator Affiliation:
Novartis
Authority:
Canada: Health Canada
Study ID:
CZOL446GCA08
NCT ID:
NCT00247650
Start Date:
September 2005
Completion Date:
Related Keywords:
- Breast Cancer
- neoadjuvant, postmenopausal women, breast cancer, hormonal therapy, bisphosphonate
- Breast Neoplasms